Share Name Share Symbol Market Type Share ISIN Share Description
Venn Life LSE:VENN London Ordinary Share GB00B9275X97 ORD 0.1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.00p +0.00% 13.75p 13.50p 14.00p 13.75p 13.75p 13.75p 2,000 06:30:37
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 15.3 -0.8 0.8 17.5 8.29

Venn Life Share Discussion Threads

Showing 1276 to 1298 of 1300 messages
Chat Pages: 52  51  50  49  48  47  46  45  44  43  42  41  Older
DateSubjectAuthorDiscuss
24/7/2017
10:23
Hybridan brought out a new note on Thursday envisaging a 30p+ share price on delivery of 2017 forecasts. Their forecasts are: this year : €1.83 EPS, €3.62m cash pile next year : €2.07 EPS, €4.03m cash pile "Solid H1 2017 After a lacklustre full year results released in March 2017, the growing Contract Research Organisation providing drug development, clinical trial management and resourcing solutions to pharmaceuticals, biotechnology and medical device clients today provided a trading update for the six months ended 30 June 2017. The new financial year started well with the Company securing contract wins in January and February with a value of €5.7m. Total revenues for the Company were ahead compared to the same period last year at €9.11m (H1 2016:€9.06m), with the client and revenue mix well balanced and strong rates of repeat business. Moreover, we understand that Venn, has successfully introduced and delivered cross selling between early and late phase client bases. We estimate that the Sedana contract announced in November 2016 and the €5.7m contracts won in January and February this year will contribute €4.3m in fee income in the current year. The Company has a strong proposal book, which should begin to turn in to business wins now that the full R&D lifecycle proposition is up and running. In addition to this, solid first half performance brings confidence around full year revenue expectations. The sector continues to see growth, with encouraging trends in outsourcing likely to continue. We would expect that Venn continues to evaluate complementary acquisition targets which could at least in part be funded from its current balance sheet depending on size. The Company is well positioned to accelerate its win rate particularly with Biotechnology companies where its offering of a full lifecycle service combined with a customer-centric flexible approach sets it apart from the competition. The shares of Venn have slid by 11% over the past 3 months, and given this trading update and its potential to meet expectations for full-year results, it presents a potential buying opportunity for investors. Delivery of our 2017 forecasts should see a recovery in the share rating and we see scope for the shares to surpass 30p over that horizon which would put the shares on a 16.5x 2018 earnings rating. Cash and cash equivalents remained strong at €3.4m at 31 December 2016 and we are forecasting for FY 2017 cash and cash equivalents of £3.6m. With that said, a HY 2017 cash of €2.9m puts the Company in a strong cash position."
rivaldo
24/7/2017
07:44
I think our freind yump might be able to concoct a case to make you ponder Dibbs
buywell3
20/7/2017
20:51
I did hold a while back but did sell out for a small loss. It is a share that I still keep an eye on. The update sounds broadly positive but they talk of "confidence around full year revenue expectations" There is no reference to profitability which leaves me feeling less positive than I was after my initial read. Anyone else see it this way? Cheers Dibbs
dibbs
20/7/2017
19:16
If it looks like a dog, smells like a dog and barks like a dog then it's a dog!!!LBO - 26 Apr 2017 - 10:27 - 940 of 993 The only thing this crowd is qualified to do is sell fivers for a pound at shareholders expense! Just like at Alltracel they will keep raising money for as long as they can get away with it and then when shareholders realise what's going on and no more fools can be found to buy what they selling they will sell the whole lot out at a fraction of what was put in by shareholders and walk off into the sunset with their salaries and cash from options they managed to dump also.
lbo
20/7/2017
18:03
Beauforts Boilers Does have a nice ring to it Don't answer if they ring again Unless your radiators are making a noise or leaking
buywell3
20/7/2017
17:21
I'm still holding from 30p but feel nervous about this company and should have bailed on a stop loss ages ago I guess! I've had a number of shares where Beauforts have been broker and they've nearly all gone down the pan. Any company they are associated with I now avoid like the plague and have had to block them on my phones as they kept pestering me! Are they some kind of Boiler Room outfit? :(
jpuff
20/7/2017
16:46
So what The market has spoken
buywell3
20/7/2017
14:25
New note from Hybridan concludes: 'Delivery of our 2017 forecasts should see a recovery in the share rating and we see scope for the shares to surpass 30p over that horizon which would put the shares on a 16.5x 2018 earnings rating. Cash and cash equivalents remained strong at €3.4m at 31 December 2016 and we are forecasting for FY 2017 cash and cash equivalents of £3.6m. With that said, a HY 2017 cash of €2.9m puts the Company in a strong cash position.'
penpont
20/7/2017
07:47
I have noted a number of staff positions becoming vacant/advertised in Holland Plus the Kinesis owner has left VENN
buywell3
20/7/2017
07:44
Yes, should restore confidence. Healthy outlook an increase in cash and the SKIN stake - yet a miserly valuation.
chadders
20/7/2017
07:40
Euros 260k more turnover, that is 3% increase (which is why no %age was mentioned) But with a now increased and increasing headcount due to acquisition staff Admin costs associated with such go up, hence VENN is flatlining at best dyor
buywell3
20/7/2017
07:25
Well a very short to the point TU from Venn with no nasty surprises. Looks all ok & board confident going forward, which is a bonus. Good luck holders, you all deserve some reward for your patience.
cocker
20/7/2017
07:18
Pretty solid H1 trading statement, in particular expressing confidence going forward, which should restore some confidence. Note the €2.9m cash against the £9m m/cap: Https://www.investegate.co.uk/venn-life-sciences--venn-/rns/half-year-end-update/201707200700075675L/ "The new financial year started well with contract wins of €5.7m secured in January and February, as previously announced. Overall, the Company has achieved total revenues of €9.1m (H2 2016 €8.84m) for the first six months of the year. Our client and revenue mix remains well balanced with strong rates of repeat business and we have successfully delivered initial cross sales between the early and late phase client bases. We have a strong proposals book which coupled with this solid first half performance provides confidence around full year revenue expectations. We finished the first half year with a cash position of €2.9m (€1.75m as at 30 June 2016)."
rivaldo
12/7/2017
13:10
Exactly Chadders. Obviously TU came along side an agm statement which has already gone. However, they will know numbers & should release ASAP
cocker
12/7/2017
11:18
First half numbers last year were announced September. Maybe get a trading update though.
chadders
12/7/2017
07:20
1/2 year figures must be know within reason, therefore investors should expect news soon from the company. Failure to do so will only start ringing alarm bells for me, as these tiddler's all to often are more than prepared to put out any good news.
cocker
06/7/2017
16:59
Some people sell low and buy high, which suits me ;-)
yump
06/7/2017
11:37
??? why would you want to sell at this sp
harry vederci
06/7/2017
09:24
Still can't sell in size.....
mrphiljones
06/7/2017
09:15
More small buying coming in - having a decent effect on the share price too.
rivaldo
05/7/2017
14:58
Agreed rivaldo, since the finals Venn has fallen from 20p, a tad frustrating when there's been little trading and a very positive outlook "The strong momentum enjoyed by the business in 2016 has continued into 2017 to date. In the first two months of 2017, we have secured new contracts valued at EUR5.7m and our pipeline of opportunities is healthy. We will continue to expand our geographical coverage and further develop emerging areas of specialism during 2017. Our industry sector continues to deliver good growth and clear opportunities exist for Venn to grow both organically and through acquisition"
chadders
05/7/2017
14:23
About time :o))
rivaldo
05/7/2017
11:40
Some nice buys going through. Just perhaps a sign of a good update coming. You guys deserve some for sure
cocker
Chat Pages: 52  51  50  49  48  47  46  45  44  43  42  41  Older
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:34 V: D:20170726 10:53:27